与二肽基肽酶-4抑制剂（DPP4i）使用者相比，钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）使用者发生结直肠癌的风险更低：一项采用竞争风险分析的倾向评分匹配研究。 - Suppr

Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis.

作者信息

Chan Raymond Ngai Chiu, Chan Robert Ngai Fung, Chou Oscar Hou In, Tse Gary, Lee Sharen

机构信息

Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China.

Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China; Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.

出版信息

Eur J Intern Med. 2023 Apr;110:125-127. doi: 10.1016/j.ejim.2023.01.021. Epub 2023 Jan 31.

DOI:10.1016/j.ejim.2023.01.021

PMID:36732129

Abstract

摘要

相似文献

Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis.与二肽基肽酶-4抑制剂（DPP4i）使用者相比，钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）使用者发生结直肠癌的风险更低：一项采用竞争风险分析的倾向评分匹配研究。

Eur J Intern Med. 2023 Apr;110:125-127. doi: 10.1016/j.ejim.2023.01.021. Epub 2023 Jan 31.

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.2型糖尿病患者中，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂相比二肽基肽酶-4（DPP4）抑制剂，痛风风险更低。

Rheumatology (Oxford). 2023 Apr 3;62(4):1501-1510. doi: 10.1093/rheumatology/keac509.

Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.比较钠-葡萄糖共转运蛋白 2 抑制剂和二肽基肽酶-4 抑制剂对新发抑郁症的影响：香港一项倾向评分匹配研究。

Acta Diabetol. 2023 Jul;60(7):917-927. doi: 10.1007/s00592-023-02063-6. Epub 2023 Mar 31.

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂治疗 2 型糖尿病患者新发心房颤动的风险：一项全国性队列研究。

Cardiovasc Diabetol. 2022 Jun 28;21(1):118. doi: 10.1186/s12933-022-01549-x.

Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.在中国香港，钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂的使用与 2 型糖尿病患者发生阻塞性气道疾病和加重事件的风险相关。

JAMA Netw Open. 2023 Jan 3;6(1):e2251177. doi: 10.1001/jamanetworkopen.2022.51177.

Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂使用者中的心力衰竭和心肌梗死事件。

ESC Heart Fail. 2022 Apr;9(2):1388-1399. doi: 10.1002/ehf2.13830. Epub 2022 Feb 7.

Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis.钠-葡萄糖协同转运蛋白 2 抑制剂与 2 型糖尿病患者死亡率降低的相关性及死因分析。

Sci Rep. 2022 Jun 16;12(1):10147. doi: 10.1038/s41598-022-13760-7.

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂治疗 2 型糖尿病患者新发心房颤动的风险。

Cardiovasc Diabetol. 2020 Nov 6;19(1):188. doi: 10.1186/s12933-020-01162-w.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与二肽基肽酶-4（DPP4）抑制剂治疗新发痴呆症的比较：一项基于倾向评分匹配的人群研究及竞争风险分析

Front Cardiovasc Med. 2021 Oct 21;8:747620. doi: 10.3389/fcvm.2021.747620. eCollection 2021.

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.二肽基肽酶-4 抑制剂可降低 2 型糖尿病患者心房颤动的风险：来自台湾的全国性队列研究。

Cardiovasc Diabetol. 2017 Dec 19;16(1):159. doi: 10.1186/s12933-017-0640-5.

引用本文的文献

Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis.糖尿病患者中与钠-葡萄糖协同转运蛋白抑制剂（SGLT抑制剂）和二肽基肽酶-4抑制剂（DPP-4抑制剂）相关的癌症比较风险：一项系统评价和荟萃分析

Diabetol Metab Syndr. 2025 Aug 7;17(1):321. doi: 10.1186/s13098-025-01898-z.

Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology-a narrative review.揭示SGLT-2抑制剂的抗癌潜力：临床肿瘤学中的机制与前景——一篇叙述性综述

Eur J Med Res. 2025 Jun 24;30(1):520. doi: 10.1186/s40001-025-02749-3.

Association between sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis of randomized active-controlled trials.钠-葡萄糖协同转运蛋白2抑制剂与癌症之间的关联：一项对随机活性对照试验的系统评价和荟萃分析

Int J Clin Pharm. 2025 Apr 28. doi: 10.1007/s11096-025-01924-0.

Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis.新型抗糖尿病药物使用与癌症风险及保护作用关联的真实世界证据：一项系统综述和网状Meta分析。

Ther Adv Drug Saf. 2025 Apr 21;16:20420986251335214. doi: 10.1177/20420986251335214. eCollection 2025.

Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination.接受二甲双胍、SGLT-2抑制剂或二者联合治疗的2型糖尿病患者患结直肠癌及癌症相关死亡率的风险

Cancer Commun (Lond). 2025 Jul;45(7):880-883. doi: 10.1002/cac2.70028. Epub 2025 Apr 24.

Advances in sodium-glucose transporter protein 2 inhibitors and tumors.钠-葡萄糖转运蛋白2抑制剂与肿瘤的研究进展

Front Oncol. 2025 Feb 11;15:1522059. doi: 10.3389/fonc.2025.1522059. eCollection 2025.

Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.二肽基肽酶-4抑制剂对2型糖尿病患者结直肠癌发病率的影响：一项系统评价和荟萃分析

Ther Adv Drug Saf. 2025 Feb 19;16:20420986251318842. doi: 10.1177/20420986251318842. eCollection 2025.

Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities.探索SGLT2抑制剂在癌症中的作用：作用机制与治疗机会

Cancers (Basel). 2025 Jan 30;17(3):466. doi: 10.3390/cancers17030466.

Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.SGLT2 抑制剂对疑似 MASLD 的 2 型糖尿病患者食管静脉曲张和肝外癌症发生的影响：日本全国数据库研究。

J Gastroenterol. 2024 Dec;59(12):1120-1132. doi: 10.1007/s00535-024-02158-z. Epub 2024 Oct 11.

Obesity-Associated Colorectal Cancer.肥胖相关性结直肠癌。

Int J Mol Sci. 2024 Aug 14;25(16):8836. doi: 10.3390/ijms25168836.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献